companiesCompany
Sumitomo Pharma (Myovant)
Sumitomo Pharma makes Orgovyx (relugolix), the first oral GnRH antagonist for prostate cancer.
Acquired Myovant Sciences (2023). Relugolix (HERO trial) offers rapid, reversible testosterone suppression without the flare of GnRH agonists and with fewer major cardiovascular events in HERO.
Pages like this
not linked directly; found by shared links- PathwayAndrogen receptor signalling
Shares Relugolix, Prostate cancer.
- TechnologyAndrogen deprivation & AR pathway inhibitors
Shares Relugolix, Prostate cancer.